Matrix metalloproteinases as modulators of inflammation and innate immunity

By W. Parks, Carole L Wilson, Y. S. López-Boado. Nature reviews. Immunology, 2004

1,944 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/f0d28707b20b6cf717364b245811b6f10b738d0e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Gillian Murphy
2. Hideaki Nagase
3. W. Parks
4. P. E. Van den Steen
5. G. Opdenakker
6. S. Gill
7. Zena Werb
8. J. Vandooren

In Molecular Biology

1. Gillian Murphy
2. S. Gill
3. Hideaki Nagase
4. W. Parks
5. V. Plaks
6. G. Opdenakker
7. J. Vandooren
8. P. E. Van den Steen

In Oncology

1. Gillian Murphy
2. Hideaki Nagase
3. W. Parks
4. S. Gill
5. Zena Werb
6. G. Opdenakker
7. H. Ra
8. V. Plaks

Citations in the corpus

• Metalloproteinases and Wound Healing (2015, background): “Epithelial, stromal, or inflammatory cell expression of MMPs can control inflammation in the wound area through the regulation of chemokine activity.(18) MMP-1, MMP-3, and MMP-9 are the major chemokine regulators during wound healing, degrading chemokines by proteolysis to remove them entirely or to”
• Metalloproteinases and their inhibitors: regulators of wound healing. (2008, background): “…bioactive molecules such as growth factors, cytokines and chemokines, as well as their respective receptors, the ability to degrade ECM proteins has been demonstrated for some members of the MMP family using gain- or loss-of-function approaches (McCawley & Matrisian, 2001; Parks et al., 2004).”
• Matrix metalloproteinases as modulators of inflammation. (2008, background): “Such approaches include evaluating co-localization of the proteinase and its substrate, determining the cleavage site(s) and specificity by targeted mutagenesis, and evaluating loss-of-function and gain-of-function in in vivo systems [1].”
• Genetic association between polymorphisms in the BTG1 gene and multiple sclerosis. (2005, neutral): “Genes encoding metalloproteinases are attractive candidates to study MS due to their role in brain extracellular matrix (ECM) cleavage and regulation of inflammation and acquired immunity (Romanic and Madri, 1994; Parks et al., 2004).”
• Progress in matrix metalloproteinase research. (2008, background): “It degrades ECM components, but it also cleaves cell surface molecules such as Fas–ligand, protumor necrosis factor α, syndecan 1 and E-cadherin to generate soluble forms, hence acting as a form of ‘sheddase’ (Parks et al., 2004).”
• Matrix Metalloproteinases: Regulators of the Tumor Microenvironment (2010, background): “There is strong evidence from studies in knockout mice that MMPs play an important role in acute as well as chronic inflammation (Parks et al., 2004).”
• Control of matrix metalloproteinase catalytic activity. (2007, background): “…inflammatory, tumor) express several, different MMPs, and these proteinase can either promote or restrain disease or repair processes by affecting multiple and apparently opposing processes by the same cell at the same time (Coussens et al., 2002; Egeblad and Werb, 2002; Parks et al., 2004).”
• The role of TIMPs in regulation of extracellular matrix proteolysis. (2015, background): “In the current paper, various MMPs and ADAMs will be mentioned as it pertains to the role of the different TIMPs; however, complete descriptions of these metalloproteinases is beyond the scope of the current paper and can be found in a number of excellent reviews [4–7].”
• Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation (2007, background): “Inflammatory conditions are almost always characterized by deregulated, often increased MMP activities [5].”